PRE Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- 0.00
- P/B
- 2.51
- P/S (TTM)
- 2.72
- EV/EBITDA
- 0.14
Profitability & growth
- ROE (TTM)
- -40.8%
- Operating margin
- -24.7%
- Revenue growth YoY
- 107.7%
- Dividend yield
- —
- Beta
- 0.25
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Prenetics Global Ltd
Company profilePrenetics Global Ltd (PRE) is an innovative health technology company that specializes in advanced genetic and diagnostic testing solutions, offering invaluable health insights to consumers and healthcare professionals alike. With a robust focus on research and development, Prenetics has built a strong international footprint through strategic partnerships and collaborations, enhancing its market visibility. As a frontrunner in personalized medicine, the company is strategically positioned to leverage the growing demand for accessible health data, presenting a compelling investment…
Classification
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- UNIT 703-706, K11 ATELIER KING?S ROAD, QUARRY BAY
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer